drugset / Trial / NCT01211002
Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 4
Unknown
170 enrolled
Simcere Pharmaceutical Co., Ltd
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
It is a trials to evaluate the overall survival (OS) of radiotherapy / EP combined with recombinant human endostatin in treatment of locally advanced (Ⅲ A / unresectable Ⅲ B) non-small cell lung cancer.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 50 mg/m2 | — |
| Background | Etoposide | Small molecule | 50 mg/m2 | — |